S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Cassava Sciences Stock Forecast, Price & News

-1.61 (-5.73%)
(As of 07/1/2022 05:44 PM ET)
Today's Range
50-Day Range
52-Week Range
754,654 shs
Average Volume
1.64 million shs
Market Capitalization
$1.06 billion
P/E Ratio
Dividend Yield
Price Target

Cassava Sciences Stock Forecast (MarketRank)

Analyst Rating
2.40 Rating Score
368.7% Upside
$124.25 Price Target
Short Interest
27.37% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.57mentions of Cassava Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.75) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.85 out of 5 stars

Medical Sector

755th out of 1,429 stocks

Pharmaceutical Preparations Industry

363rd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Cassava Sciences logo

About Cassava Sciences (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-32.38 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$6.35 per share


Free Float
Market Cap
$1.06 billion
Not Optionable

Cassava Sciences Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Cassava Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View analyst ratings for Cassava Sciences
or view top-rated stocks.

What is Cassava Sciences' stock price forecast for 2022?

5 Wall Street research analysts have issued 1-year target prices for Cassava Sciences' shares. Their SAVA stock forecasts range from $58.00 to $215.00. On average, they predict Cassava Sciences' share price to reach $124.25 in the next twelve months. This suggests a possible upside of 368.7% from the stock's current price.
View analysts' price targets for Cassava Sciences
or view top-rated stocks among Wall Street analysts.

How has Cassava Sciences' stock performed in 2022?

Cassava Sciences' stock was trading at $43.70 at the beginning of the year. Since then, SAVA shares have decreased by 39.3% and is now trading at $26.51.
View the best growth stocks for 2022 here

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Cassava Sciences

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings data on Thursday, May, 5th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02.
View Cassava Sciences' earnings history

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Cassava Sciences's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, Pres & CEO (Age 62, Pay $1.74M)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 54, Pay $776.93k)
  • Dr. Nadav Friedmann M.D., Ph.D., Chief Medical Officer & Director (Age 79, Pay $765k)
  • Dr. James W. Kupiec M.D., Chief Clinical Devel. Officer
  • Dr. George Thornton, Sr. VP of Technology
  • Mr. Michael Zamloot, Sr. VP of Technical Operations
  • Dr. Lindsay H. Burns Ph.D., Sr. VP of Neuroscience

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $26.51.

How much money does Cassava Sciences make?

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.06 billion. The company earns $-32.38 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Cassava Sciences have?

Cassava Sciences employs 24 workers across the globe.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for Cassava Sciences is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at [email protected], or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.